drugset / Trial / NCT04829604
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NaSingle-groupOpen-labelTreatment
Summary
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Timeline
- Start
- 2021-10-26
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANVATABART OPADOTIN | Other / unclassified | — | Intravenous |